JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the Company received approval from the European Commission to proceed with its acquisition of ratiopharm. In connection with this approval and following the Commission’s review of this transaction, Teva made certain limited commitments, which are anticipated to have only a marginal affect on the combined companies’ activities. Teva now plans to close the transaction in the near future.
